"Ranitidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.
Descriptor ID |
D011899
|
MeSH Number(s) |
D03.383.312.750
|
Concept/Terms |
Ranitidine- Ranitidine
- Ranitidin
- N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine
|
Below are MeSH descriptors whose meaning is more general than "Ranitidine".
Below are MeSH descriptors whose meaning is more specific than "Ranitidine".
This graph shows the total number of publications written about "Ranitidine" by people in this website by year, and whether "Ranitidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 1 | 0 | 1 |
1998 | 0 | 1 | 1 |
2005 | 1 | 0 | 1 |
2006 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ranitidine" by people in Profiles.
-
Singh K, Maung P, Vadivelu K. Ranitidine-Associated Autoimmune Hepatitis. Am J Ther. 2018 Nov/Dec; 25(6):e758-e760.
-
Khan AY, Kalimuddin MN, Gorman JM. Neuropsychiatric manifestations of phenytoin toxicity in an elderly patient. J Psychiatr Pract. 2007 Jan; 13(1):49-54.
-
Ancha HR, Ancha HB, Tedesco DS, Ward AR, Harty RF. Inhibition of epidermal growth factor receptor activation enhances in vivo histamine-stimulated gastric acid secretion in the rat. Dig Dis Sci. 2006 Feb; 51(2):274-81.
-
Swanson KA. OTC product: maximum strength Zantac 150. J Am Pharm Assoc (2003). 2005 Jul-Aug; 45(4):528.
-
Orenstein SR, Blumer JL, Faessel HM, McGuire JA, Fung K, Li BU, Lavine JE, Grunow JE, Treem WR, Ciociola AA. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2002 May; 16(5):899-907.
-
Orr WC, Harnish MJ. Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment Pharmacol Ther. 1998 Oct; 12(10):1033-8.
-
Orr WC, Mellow MH, Grossman MR. Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression. Aliment Pharmacol Ther. 1995 Oct; 9(5):571-4.
-
Orr WC, Duke JC, Imes NK, Mellow MH. Comparative effects of H2-receptor antagonists on subjective and objective assessments of sleep. Aliment Pharmacol Ther. 1994 Apr; 8(2):203-7.
-
Russell J, Orr WC, Wilson T, Finn AL. Effects of ranitidine, given t.d.s., on intragastric and oesophageal pH in patients with gastrooesophageal reflux. Aliment Pharmacol Ther. 1991 Dec; 5(6):621-30.
-
Orr WC, Finn A, Wilson T, Russell J. Esophageal acid contact time and heartburn in acute treatment with ranitidine and metoclopramide. Am J Gastroenterol. 1990 Jun; 85(6):697-700.